Please login to the form below

Not currently logged in
Email:
Password:

Merkel cell carcinoma

This page shows the latest Merkel cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Pfizer poaches cancer R&D head Jeff Settleman from Calico

Pfizer poaches cancer R&D head Jeff Settleman from Calico

That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna (talazoparib) for breast cancer, Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro ... Settleman comes in as

Latest news

  • Merck claims key FDA okay for Bavencio in kidney cancer Merck claims key FDA okay for Bavencio in kidney cancer

    The FDA has just approved Pfizer-partnered Bavencio (avelumab) in combination with Pfizer’s Inlyta (axitinib) as a first-line therapy for patients with advanced renal cell carcinoma (RCC), the most ... For a while, Bavencio is was the only PD-1/PD-L1

  • Vyriad inks immunotherapy alliance with Merck/Pfizer Vyriad inks immunotherapy alliance with Merck/Pfizer

    The drug – sold as Bavencio – has been approved for skin cancer Merkel cell carcinoma and bladder cancer, but in February failed a trial as a second-line therapy for non-small ... cell lung cancer and also had a knockback in third-line stomach cancer

  • Immuno-oncology at ASCO: survival data, combinations and new indications Immuno-oncology at ASCO: survival data, combinations and new indications

    BMS will also present new data on Opdivo in Merkel cell carcinoma and triple-negative breast cancer (TNBC). ... in small-cell lung cancer, gastric or gastroesophageal junction (G/GEJ) cancer and Merkel cell carcinoma.

  • Merck and Pfizer set to win NICE backing for Bavencio Merck and Pfizer set to win NICE backing for Bavencio

    In a final appraisal determination, the UK’s cost-effectiveness body is set to give the drug the all clear to treat patients with previously treated metastatic Merkel Cell Carcinoma (mMCC) ... to access the first targeted systemic treatment option

  • Merck/Pfizer’s cancer immunotherapy latecomer hits a snag Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

    Fourth-to-market in the PD-1/PD-L1 checkpoint inhibitor category, Bavencio (avelumab) is already approved for skin cancer Merkel cell carcinoma and bladder cancer, but hopes of extending its ... For now, it faces a tough marketing battle in bladder

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics